Apogee Therapeutics, Inc Common Stock
Price & Volume
Stats
See moreOpen | $38.62 |
Previous Close | $38.42 |
Day Range | $37.01-$38.62 |
52W Range | $26.20-$63.50 |
Market Cap | $2.2B |
Shares Short | 9M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$4.14 |
News
See moreYahoo Finance • 10 days ago
BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis
Yahoo Finance • 14 days ago
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
Yahoo Finance • 22 days ago
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
Yahoo Finance • last month
InvestingPro Fair Value model captures 43% downside in Apogee Therapeutics
About
CEO | Dr. Michael Thomas Henderson M.D. |
Address | Building 17, Waltham, MA, United States, 02453 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 196 |
